ANNX
Annexon, Inc.
Key Financials
Operating Income
$-216407000
↓ 40.5%
Total Liabilities
$65.9M
↑ 15.7%
EPS (Diluted)
$-1.34
↓ 32.7%
Net Income
$-206690000
↓ 49.6%
Shareholders' Equity
$211.6M
↓ 27.8%
Total Assets
$277.6M
↓ 20.7%
Cash & Equivalents
$162.1M
↑ 227.4%
Dividends/Share
$0.00
NaN%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/25/2026 | View on SEC |
| 144 | 8/13/2026 | View on SEC |
| 4 | 8/12/2026 | View on SEC |
| 3 | 8/12/2026 | View on SEC |
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 8-K | 7/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ANNX |
| Company Name | Annexon, Inc. |
| CIK | 1528115 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 822-5500 |